Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

264 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Research Priorities for Precision Medicine in NAFLD.
Iruzubieta P, Bataller R, Arias-Loste MT, Arrese M, Calleja JL, Castro-Narro G, Cusi K, Dillon JF, Martínez-Chantar ML, Mateo M, Pérez A, Rinella ME, Romero-Gómez M, Schattenberg JM, Zelber-Sagi S, Crespo J, Lazarus JV. Iruzubieta P, et al. Among authors: calleja jl. Clin Liver Dis. 2023 May;27(2):535-551. doi: 10.1016/j.cld.2023.01.016. Epub 2023 Feb 26. Clin Liver Dis. 2023. PMID: 37024222 Review.
Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain.
Turnes J, Romero-Gómez M, Planas R, Solà R, García-Samaniego J, Diago M, Crespo J, Calleja JL, Rubio-Terrés C, Ventayol P. Turnes J, et al. Among authors: calleja jl. Gastroenterol Hepatol. 2013 Nov;36(9):555-64. doi: 10.1016/j.gastrohep.2013.08.003. Epub 2013 Oct 9. Gastroenterol Hepatol. 2013. PMID: 24119723
Reply to: "Renal impairment and anemia during triple therapy".
Romero-Gómez M, Berenguer M, Molina E, Calleja JL. Romero-Gómez M, et al. Among authors: calleja jl. J Hepatol. 2014 May;60(5):1100-1. doi: 10.1016/j.jhep.2014.01.007. Epub 2014 Jan 18. J Hepatol. 2014. PMID: 24445218 Free article. No abstract available.
Prediction of week 4 virological response in hepatitis C for making decision on triple therapy: the Optim study.
Romero-Gómez M, Turnes J, Ampuero J, Oyagüez I, Cuenca B, Gonzalez-Garcia J, Muñoz-Molina B, Aguilar R, Leal S, Planas R, Garcia-Samaniego J, Diago M, Crespo J, Calleja JL, Casado MA, Sola R. Romero-Gómez M, et al. Among authors: calleja jl. PLoS One. 2015 Mar 31;10(3):e0122613. doi: 10.1371/journal.pone.0122613. eCollection 2015. PLoS One. 2015. PMID: 25826755 Free PMC article.
High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain.
Crespo J, Diago M, Cabezas J, Berenguer M, Broquetas T, Serra MÁ, Morillas R, García-Samaniego J, Calleja JL, Sánchez JJ, Lens S, Soto-Fernández S, Sacristán B, Fernández I, López-Núñez C, Buti M, Romero-Gómez M, Sáez-Royuela F, Fernández C, Jorquera F, Sánchez-Antolín G, Pascasio JM, Cuadrado A, Hernández-Guerra M. Crespo J, et al. Among authors: calleja jl. Ann Hepatol. 2015 Jul-Aug;14(4):477-86. Ann Hepatol. 2015. PMID: 26019034 Free article.
Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment.
Ampuero J, Del Campo JA, Rojas L, Calleja JL, Cabezas J, Lens S, Crespo J, Forns X, Andrade RJ, Fernández I, Buti M, Millán R, Romero-Gómez M. Ampuero J, et al. Among authors: calleja jl. J Clin Virol. 2015 Jul;68:56-60. doi: 10.1016/j.jcv.2015.05.010. Epub 2015 May 14. J Clin Virol. 2015. PMID: 26071337
264 results